NCT05853861 (PETAL) is a NA clinical trial of JASPER Babble in MONITOR, sponsored by University of California, Los Angeles.

Who is sponsoring NCT05853861?

NCT05853861 is sponsored by University of California, Los Angeles.

What drugs are being tested in NCT05853861?

Interventions in NCT05853861: JASPER Babble.

What condition does NCT05853861 study?

NCT05853861 studies MONITOR, COACH.

Is NCT05853861 still recruiting?

NCT05853861 is currently recruiting now. Last updated 31 March 2026.

Last reviewed 2026-03-31 · How we verify

NCT05853861: PETAL

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Promoting Early Intervention Timing and Attention to Language

Recruiting now NA Last updated 31 March 2026

What this trial tests

NA trial testing JASPER Babble in MONITOR in 140 participants. Currently enrolling.

Timeline

25 November 2024

Primary endpoint
31 December 2027

30 June 2028

Quick facts

Lead sponsor	University of California, Los Angeles
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	140
Start date	25 November 2024
Primary completion	31 December 2027
Estimated completion	30 June 2028
Sites	2 locations across United States

Drugs / interventions tested

JASPER Babble

Conditions studied

MONITOR — all drugs for MONITOR →
COACH — all drugs for COACH →

Sponsor

University of California, Los Angeles

Who can join

Adults 6 Months to 8 Months, any sex, with MONITOR or COACH. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The proposed study (PETAL: Promoting Early intervention Timing and Attention to Language) aims to determine the timing of intervention among infants with Increased Likelihood for Autism (ILA; at risk for autism by virtue of having an older sibling with autism) on communication and language outcomes at 24 months. Results of this study will determine when (9 vs 12 vs 15 months), and based on which measures (brain, language, or their combination) to augment parental support with a specialized parent-mediated coaching intervention for optimal outcomes on communication and language at 24 months. Children will be recruited at 6-8 months of age and will begin with entry assessments. All children will first begin with the MONITOR condition (using Ages \& Stages Questionnaire (ASQ-3) and activity cards. Then when the child is 9 months, they will be randomized to continue with MONITOR condition or COACH condition (i.e. JASPER Babble) after second set of assessments. There are a total of 6 assessment timepoints (6-8 months of age, 9 months of age, 12 months of age, 15 months of age, 18 months of age, and 24 months of age). At time points of 9months and 12 months, the child will be randomized to COACH or MONITOR conditions. Once the child is randomized to COACH condition, they will continue with that condition until they terminate the study at 24 months. At the 15 months timepoint, there will no longer be a randomization. Children that were in the MONITOR condition will change to the COACH condition until they terminate the study.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other University of California, Los Angeles trials

Trials by the same sponsor.

NCT04846517 — rTMS for Aneroxia Nervosa in Youth · NA · not yet recruiting
NCT06701760 — Sodium Lactate in Severe TBI · Phase 2 · not yet recruiting
NCT04996667 — Effect of iNO in Patients With Submassive and Massive PE · Phase 2 · withdrawn
NCT05067387 — Evaluation of Oral THC and CBD in Men and Women · Phase 1 · not yet recruiting
NCT07534696 — Evaluation of Non-Invasive Pelvic Floor Neuromuscular Stimulation for Urinary Incontinence After Prostatectomy · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05853861 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, Los Angeles
Last refreshed: 31 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05853861.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing